Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 7/20 | 0.46 |
| ▸ | RXRB | P28702 | 7/20 | 0.46 |
| ▸ | RXRG | P48443 | 6/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13454135 | 0.90 | MAPT (0.42) | GAAMAPTRXRARXRBRXRG | |
| SCHEMBL12676292 | 0.87 | GAA (0.42) | GAAMAPTRXRARXRBRXRG | |
| SCHEMBL12676374 | 0.85 | GAA (0.56) | GAAMAPTRXRARXRBRXRG | |
| SCHEMBL1898926 | 0.84 | MAPT (0.52) | GAAMAPTKDM1AHTR2C | |
| SCHEMBL5329450 | 0.84 | MAPT (0.57) | GAAMAPTKDM1AHTR2C | |
| SCHEMBL12676291 | 0.81 | GAA (0.46) | GAAMAPTKDM1AHTR2CKIF11 | |
| SCHEMBL12676272 | 0.78 | GAA (0.43) | GAAMAPTKDM1AHTR2CBACE1 | |
| SCHEMBL427824 | 0.77 | HTR2C (0.53) | GAAMAPTKDM1AHTR2C | |
| SCHEMBL12676320 | 0.77 | GAA (0.45) | GAAMAPTRXRARXRBKDM1A | |
| SCHEMBL12676293 | 0.77 | GAA (0.42) | GAAMAPTKDM1ATDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593069-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2016-02-11 | — | — | US | disclosed |
| US-9162968-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140371313-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2014-12-18 | — | — | US | disclosed |
| US-8722939-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120264765-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2011059821-A2 | CYCLOHEXANE-1,3-DIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371313-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | GAA 48/4885MAPT 259/4885RXRA 2639/4885 |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | GAA 48/4885MAPT 259/4885RXRA 2639/4885 |
| US-20120264765-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | GAA 48/4885MAPT 259/4885RXRA 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.